NasdaqCM - Nasdaq Real Time Price ? USD Dermata Therapeutics, Inc. (DRMA) Follow Compare 1.3500 +0.0900 (+7.14%) At close: November 6 at 4:00 PM EST 1.3400 -0.01 (-0.74%) After hours: November 6 at 5:25 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024 SAN DIEGO, CA / ACCESSWIRE / October 8, 2024 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, ... ACCESSWIRE ? 29 days ago DRMA +7.14% DRMAW Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules Dermata raises approximately $7.8 million in gross proceeds since May 2024 - expected to fund its operations into the second quarter of 2025 SAN DIEGO, CA / ACCESSWIRE / September 17, 2024 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," ... ACCESSWIRE ? last month DRMA +7.14% DRMAW Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules SAN DIEGO, CA / ACCESSWIRE / September 16, 2024 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, ... ACCESSWIRE ? last month DRMA +7.14% DRMAW Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024 SAN DIEGO, CA / ACCESSWIRE / September 5, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today ... ACCESSWIRE ? 2 months ago DRMA +7.14% DRMAW 7 F-Rated Growth Stocks to Avoid Like the Plague in August 2024 What do you call a growth stock that isn’t growing any more? The answers are many. You can call it a disappointment. A drain on your portfolio. A bad investment. Any of these are true of F-rated growth stocks, as evaluated by the Portfolio Grader. And in today’s market, you can ill-afford to a bad investment. The market is in some turmoil this summer.InvestorPlace - Stock Market News, Stock Advice & Trading Tips I know it’s only temporary, but times like these are when some investors start to pa InvestorPlace ? 2 months ago MULN NIO SEDG Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results - DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial has enrolled over 50% of patients - Dermata continues discussions with potential botulinum toxin partners for DMT410 - Raised $2.3 million in net proceeds from financing ... ACCESSWIRE ? 2 months ago DRMA +7.14% DRMAW Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne - STAR-1 topline results expected in first quarter of 2025 - - About 30 million acne patients seek treatment in the U.S. each year - - DMT310, if approved, could be the first once-weekly topical product for the treatment of acne - SAN DIEGO, CA / ... ACCESSWIRE ? 3 months ago DRMA +7.14% DRMAW Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules SAN DIEGO, CA / ACCESSWIRE / May 17, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today ... ACCESSWIRE ? 5 months ago DRMA +7.14% DRMAW Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results - DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial enrollment remains on track - - Dermata continues discussions with potential botulinum toxin partners for DMT410 - - Received issuance of Japanese patent for DMT410 for ... ACCESSWIRE ? 5 months ago DRMA +7.14% DRMAW Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now MIAMI, April 02, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Emerging Growth Conference on April 3 & 4, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting compani GlobeNewswire ? 7 months ago ELMGF SNES GCTK Dermata to Present at the Emerging Growth Conference on April 3, 2024 - Dermata to provide a corporate update followed by a live question and answer session - SAN DIEGO, CA / ACCESSWIRE / March 27, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company ... ACCESSWIRE ? 7 months ago DRMA +7.14% DRMAW Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results - Initiated enrollment of DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial in Q4 2023 - - Raised $9.1 million in gross proceeds from three financings completed in 2023 - - Received issuance of Japanese patent for DMT410 ... ACCESSWIRE ? 7 months ago DRMA +7.14% DRMAW Presenting on the Emerging Growth Conference 67 Day 1 on February 7 Register Now MIAMI, Feb. 06, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 67th Emerging Growth Conference on February 7 & 8, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting compa GlobeNewswire ? 8 months ago OPHC RFHRF STCB Dermata to Present at the Emerging Growth Conference on February 7, 2024 - Company to provide a corporate overview followed by a live question and answer session - SAN DIEGO, CA / ACCESSWIRE / February 1, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology ... ACCESSWIRE ? 9 months ago DRMA +7.14% DRMAW Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis - This is the Company's first patent issued for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis -- The Company is currently discussing partnership opportunities to advance development of DMT410 -- In 2022, ... ACCESSWIRE ? 9 months ago DRMA +7.14% DRMAW Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne - About 550 patients will be treated once weekly for 12 weeks -- STAR-1 topline results expected in first quarter of 2025 -- Acne affects about 50 million patients in the U.S. - SAN DIEGO, CA / ACCESSWIRE / December 20, 2023 / Dermata Therapeutics, ... ACCESSWIRE ? 10 months ago DRMA +7.14% DRMAW Dermata (DRMA) Up on FDA Nod to Begin Pivotal Study of Acne Drug Dermata (DRMA) announces reaching an agreement with the FDA to begin a late-stage pivotal clinical program for its acne treatment candidate, DMT310. The stock rises 7%. Zacks ? 11 months ago DRMA +7.14% ANIX Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules SAN DIEGO, CA / ACCESSWIRE / November 16, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today ... ACCESSWIRE ? 11 months ago DRMA +7.14% Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols - DMT310 Phase 3 STAR-1 (Spongilla Treatment of Acne Research) clinical trial will evaluate the efficacy and safety of once-weekly treatments of DMT310 for 12 weeks in moderate-to-severe acne patients -- Topline results from STAR-1 clinical trial ... ACCESSWIRE ? 11 months ago DRMA +7.14% Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results - Raised an aggregate of $6.8 million in gross proceeds from two financings completed in 1H 2023 -- Received positive feedback from FDA on its End of Phase 2 meeting package in June 2023 -- Completed start-up activities to support DMT310 Phase 3 STAR-1 ... ACCESSWIRE ? 11 months ago DRMA +7.14% Performance Overview Trailing total returns as of 11/6/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return DRMA S&P 500 YTD -85.25% +24.30% 1-Year -89.02% +36.04% 3-Year -99.90% +26.22%
